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A B S T R A C T
Alzheimer’s disease (AD), an age-related neurodegenerative condition, is the most common cause of dementia
among the elder people, but currently there is no treatment. A number of putative pathogenic events, particu-
larly amyloid β peptide (Aβ) accumulation, are believed to be early triggers that initiate AD. However, thus far
targeting Aβ generation/aggregation as the mainstay strategy of drug development has not led to eﬀective AD-
modifying therapeutics. Oxidative damage is a conspicuous feature of AD, but this remains poorly deﬁned
phenomenon and mechanistically ill understood. The TRPM2 channel has emerged as a potentially ubiquitous
molecular mechanism mediating oxidative damage and thus plays a vital role in the pathogenesis and pro-
gression of diverse neurodegenerative diseases. This article will review the emerging evidence from recent
studies and propose a novel ‘hypothesis’ that multiple TRPM2-mediated cellular and molecular mechanisms
cascade Aβ and/or oxidative damage to AD pathologies. The ‘hypothesis’ based on these new ﬁndings discusses
the prospect of considering the TRPM2 channel as a novel therapeutic target for intervening AD and age-related
dementia.
1. Oxidative damage in Alzheimer’s disease and dementia
It was estimated according to the World Health Organisation de-
mentia facts published in 2017 that approximately 50 million people
were living with dementia worldwide and this number is predicted to
be more than tripled by 2050. Dementia has become a pressing health,
social and ﬁnancial matter of modern society due to the increasingly
aging population and the escalating healthcare cost (The World
Alzheimer Report 2015). Despite not being treated as a natural part of
aging, dementia occurs when the brain is adversely aﬀected by various
conditions. Alzheimer’s disease (AD) represents the most common cause
of dementia and also one of the most important factors for morbidity
and mortality. It is an age-related neurodegenerative disease that
mainly aﬄicts people of 65 years and above, with the prevalence ex-
hibiting a rapid increase with age (Nussbaum and Ellis, 2003). The
brains of AD patients manifest with structural and functional loss within
hippocampus, cortex and other brain regions that are responsible for
learning, memory, problem-solving, language and perception, and thus
AD patients suﬀer from progressive decline or loss of such cognitive
functions that are essential for individuals to live a normal life.
Currently, there is no eﬀective treatment that can prevent AD or slow
down the disease progression. It is well documented that the AD brains
are presented by senile plaques with deposition of amyloid β peptides
(Aβ) surrounding neurons and by neuroﬁbrillary tangles (NFTs) formed
by hyper-phosphorylated and misfolded tau proteins inside neurons.
These histopathological hallmarks are invariably accompanied by
widespread neuroinﬂammation. Aβ peptides, with Aβ40 and Aβ42 being
the major isoforms, are generated through sequential cleavage of the
amyloid precursor protein (APP), an integral membrane protein with a
large extracellular N-terminus, a single membrane-spanning domain
and a short cytoplasmic C-terminus, by β-secretase, which is better
known as beta-site APP cleaving enzyme 1 or BACE1, and γ-secretase, a
protein complex containing presenilin 1 (PS1) (Sun et al., 2015). The
widely recognized amyloid cascade hypothesis posits that Aβ accumu-
lation, resulting from elevated generation and/or reduced clearance of
Aβ due to genetic and environmental factors as well as aging, is the
early event that directly induces neuronal death and also initiates
chronic inﬂammation, NFT formation and other pathological changes
that are harmful to neurons (Bachurin et al., 2017; Blennow et al.,
2010; Hardy and Selkoe, 2002; Selkoe and Hardy, 2016). Such a
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hypothesis for AD pathogenesis have gained strong support from pre-
clinical and clinical studies (Selkoe and Hardy, 2016) and nonetheless
evokes increasing debate, mainly because targeting Aβ generation,
aggregation or clearance as a drug development strategy, despite
having been intensively explored over the past decades, has thus far not
led to discovery of any eﬀective AD-modifying therapeutics (Bachurin
et al., 2017; Honig et al., 2018; Kumar et al., 2018; Mullard, 2016,
2017; van Dyck, 2018). A better understanding of the complicated
mechanisms underpinning AD pathogenesis and progression is urgently
required, and there are also increasing interests in identifying addi-
tional or alternative intervention targets and formulating new or dif-
ferent therapeutic concepts (Butterﬁeld, 2018; Butterﬁeld and Boyd-
Kimball, 2018; Corona et al., 2011; Guillot-Sestier et al., 2015; Jiang
et al., 2016; Onyango, 2018; Rajendran and Paolicelli, 2018; Swerdlow
et al., 2014; Weinstein, 2018; Wes et al., 2016; White et al., 2017;
Wilkins et al., 2014).
Oxidative damage is a common and conspicuous feature of AD
brains (Smith et al., 1996) and other neurodegenerative diseases (Jiang
et al., 2016). Oxidative stress results from excessive generation of re-
active oxygen species (ROS) and/or impaired ROS-scavenging me-
chanisms. Aβ-induced oxidative stress, which can in return enhance Aβ
generation via stimulating the expression and activity of β- and γ-se-
cretases (Tamagno et al., 2012), has been well recognized as one of the
primary events in AD pathogenesis and progression (Bhat et al., 2015;
Blennow et al., 2010; Butterﬁeld, 2018; Butterﬁeld and Boyd-Kimball,
2018; Hardy and Selkoe, 2002; Jiang et al., 2016; Tonnies and
Trushina, 2017; Wang et al., 2014). Oxidative damage has even been
proposed as a potential therapeutic target for treatment of neurode-
generative diseases, including AD (Jiang et al., 2016). However, the
molecular mechanisms that sense oxidative stress/ROS and cascade to
neuronal damage remain poorly deﬁned. Transient receptor potential
melastatin-related 2 (TRPM2) channel has emerged as a molecular
mechanism conferring cells with the ability to sense oxidative stress/
ROS and mediating oxidative damage (Hara et al., 2002; Wehage et al.,
2002; Zhang et al., 2003). Consistently, a number of recent preclinical
studies have accumulated strong evidence to demonstrate its crucial
role in a diversity of oxidative stress-related pathological conditions,
including ischemia-reperfusion brain damage (Alim et al., 2013;
Gelderblom et al., 2014; Huang et al., 2017; Miyanohara et al., 2018;
Nakayama et al., 2013; Shimizu et al., 2016, 2013; Ye et al., 2014),
bipolar disorder (Jang et al., 2015), Parkinson’s disease (PD) (Sun et al.,
2018), endothelial barrier dysfunction (Hecquet et al., 2008, 2014),
ischemic kidney injury (Gao et al., 2014), paracetamol overdosing-in-
duced liver damage (Kheradpezhouh et al., 2014) and diabetes (Manna
et al., 2015). This article will review the emerging evidence from recent
studies and propose a novel ‘hypothesis’ that multiple TRPM2-mediated
cellular and molecular mechanisms cascade Aβ and oxidative damage
to AD-related pathologies. The ‘hypothesis’ based on these new ﬁndings
discusses the prospect of considering the TRPM2 channel as a novel
therapeutic target for intervening AD and age-related dementia.
2. A brief introduction to the TRPM2 channel
2.1. TRPM2 channel properties and activation
Mammalian cells express a family of transient receptor potential
(TRP) ion channel proteins that can be divided on the basis of sequence
relatedness into classical (TRPC), vanilloid (TRPV), melastatin (TRPM),
ankyrin (TRPA), polycystin (TRPP) and mucolipin (TRPML) sub-
families, and these ion channels are activated by polymodal mechan-
isms and associated with a large and diverse number of functional roles
in health and disease (Clapham, 2003; Nilius, 2007; Venkatachalam
and Montell, 2007). TRPM2, as formerly known as long TRPC2, is the
second member of the TRPM subfamily (Fleig and Penner, 2004;
Perraud et al., 2001; Sano et al., 2001). The human TRPM2 gene is
located on the chromosome 21q22.3, spans approximately 90 kb and
contains 32 exons (Nagamine et al., 1998). The full-length protein
(TRPM2-L) consists of 1503 amino acid residues for the human TRPM2,
or 1507 amino acid residues for the rat or mouse TRPM2, with a pre-
dicted molecular weight of∼171-173 kDa (Hill et al., 2006; Nagamine
et al., 1998; Uemura et al., 2005). The major structural properties of
several TRP channels have been recently determined at the atomic
level, including TRPC3 (Fan et al., 2018; Tang et al., 2018), TRPC4
(Vinayagam et al., 2018), TRPC6 (Tang et al., 2018), TRPV1 (Cao et al.,
2013; Liao et al., 2013), TRPV2 (Huynh et al., 2016; Zubcevic et al.,
2016), TRPV4 (Deng et al., 2018), TRPV5 (Hughes et al., 2018), TRPA1
(Paulsen et al., 2015), TRPM4 (Autzen et al., 2018; Duan et al., 2018;
Guo et al., 2017; Winkler et al., 2017), TRPM8 (Yin et al., 2018), and
TRPML3 (Hirschi et al., 2017) as well as TRPM2 (Zhang et al., 2018).
These structures conﬁrm high conservation of the overall membrane
topology of these tetrameric ion channels. As illustrated in Fig. 1A, the
TRPM2 channel subunit comprises six transmembrane segments (S1-S6)
and intracellular N- and C-termini. Four subunits assemble the channel
complex via the conserved coiled-coil (CC) domain in the proximal C-
terminus (Fujiwara et al., 2008; Jiang, 2007; Mei et al., 2006; Tsuruda
et al., 2006). The ﬁfth and sixth transmembrane segments and the re-
entrant loop between them, from each of the four subunits, form the
aqueous pore in the centre of a tetrameric complex that is permeable to
Ca2+, Na+ and K+ (Fig. 1A) (Mederos y Schnitzler et al., 2008; Xia
et al., 2008). The TRPM2 channel is gated by intracellular ADP-ribose
(ADPR) upon binding to the TRPM2-speciﬁc NUDT9-H domain in the
Fig. 1. The structural features, activation mechanisms and subcellular
locations of the TRPM2 channel.
A, schematic illustration of the TRPM2 channel structural features. The channel
is a tetramer, with each subunit composed of intracellular N- and C-termini and
six transmembrane segments (S1-S6). The S5 and S6 and the re-entrance be-
tween them, from each of the four subunits, line the ion-conducting pathway in
the centre of the tetrameric complex that is permeable to K+, Na+ and Ca2+.
The N-terminus contains an IQ-like motif required for calmodulin-dependent
channel gating by intracellular Ca2+. The C-terminus has a coiled-coil (CC)
domain that mediates the tetrameric channel assembly, and the TRPM2-speciﬁc
NUDT9 homology (NUDT9-H) domain that provides the binding site for the
TRPM2 channel activator, ADP-ribose (ADPR). B, summary of the mechanisms
by which the TRPM2 channel is activated by reactive oxygen species (ROS).
ROS promotes ADPR generation, mainly via poly(ADPR) polymerase (PARP),
predominantly the PARP-1, and poly(ADPR) glycohydrolase (PARG) in the
nucleus and, additionally, via NADase in the mitochondria. The TRPM2 channel
is present in the plasma membrane as a Ca2+-permeable cationic channel in
many cell types including neurons, microglial cells and cerebral endothelial
cells. The TRPM2 channel has been shown to be located in the lysosomes as a
Ca2+ release channel in pancreatic β-cells and dendritic cells or in the mi-
tochondria in hippocampal neurons engaged in mitochondrial Zn2+ uptake.
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distant C-terminal tail that exhibits discernible sequence homology
with the ADPR-hydrolyzing enzyme NUDT9 (Fig. 1A) (Fliegert et al.,
2017b; Heiner et al., 2003; Kuhn et al., 2017; Kuhn and Luckhoﬀ, 2004;
Perraud et al., 2001; Yu et al., 2017). Several ADPR analogues, in-
cluding 2′-O-acetyl-ADPR, 2′-deoxy-ADPR and ADPR-2′-phosphate, are
thought to be also capable of gating the TRPM2 channel (Fliegert et al.,
2017a; Grubisha et al., 2006; Toth et al., 2015), whereas there is still
lack of consensus whether other structurally or metabolically related
compounds, such as cyclic ADPR, nicotinamide adenine dinucleotide
(NAD), nicotinic acid adenine dinucleotide, and nicotinic acid adenine
dinucleotide-2′-phosphate, directly bind to and activate the TRPM2
channel (Beck et al., 2006; Kolisek et al., 2005; Toth and Csanady,
2010; Toth et al., 2015). Intracellular Ca2+ can also open the TRPM2
channel through the IQ-like calmodulin-binding motif in the N-ter-
minus (Fig. 1A) and thus Ca2+-induced channel activation can occur
independently of ADPR or in synergy with ADPR (Du et al., 2009; Tong
et al., 2006). As already mentioned above, the TRPM2 channel is highly
sensitive to activation by ROS, gaining its reputation as an oxidative
stress sensor or mediator (Jiang et al., 2010; Knowles et al., 2013; Li
et al., 2015, 2017a; Miller and Zhang, 2011; Ru and Yao, 2014; Syed
Mortadza et al., 2015; Takahashi et al., 2011; Yamamoto and Shimizu,
2016). However, ROS activate the TRPM2 channel indirectly and
mainly via promoting ADPR generation from NAD that is mediated by p
(ADPR) polymerase (PARP), particularly PARP-1, and p(ADPR) glyco-
hydrolase (PARG) in the nucleus (Fig. 1B) (Buelow et al., 2008; Fonfria
et al., 2004; Hecquet et al., 2008; Jia et al., 2011; Jiang et al., 2010;
Park et al., 2014). There is evidence to suggest that NADase-mediated
ADPR generation from NAD in the mitochondria also contributes to
ROS-induced TRPM2 channel activation (Fig. 1B) (Perraud et al.,
2005).
2.2. TRPM2 channel expression and subcellular location
The TRPM2 channel exhibits wide tissue and cell distribution
throughout the body and is expressed in both excitable and non-ex-
citable cells (Belrose and Jackson, 2018; Jiang et al., 2010; Knowles
et al., 2013; Li et al., 2017a; Perraud et al., 2005; Sumoza-Toledo and
Penner, 2011; Syed Mortadza et al., 2015; Turlova et al., 2018). The
TRPM2 channel in many cell types examined so far functions as a Ca2+-
permeable non-selective cation channel in the plasma membrane
(Fig. 1B). Evidence also exists to suggest its localization in the mem-
branes of intracellular organelles in some cell types (Fig. 1B), for ex-
ample, in the lysosomes as a Ca2+ release channel in pancreatic β-cells,
dendritic cells and endothelial cells (Abuarab et al., 2017; Lange et al.,
2009; Manna et al., 2015; Sumoza-Toledo et al., 2011) and, as discussed
below, in the mitochondria implicated in mitochondrial Zn2+ uptake in
hippocampal neurons (Li and Jiang, 2018).
The TRPM2 channel is abundantly expressed in the brain. Its ex-
pression has been shown in hippocampal (Bai and Lipski, 2010; Belrose
et al., 2012; Jia et al., 2011; Olah et al., 2009; Verma et al., 2012; Xie
et al., 2011; Ye et al., 2014), cortical (Kaneko et al., 2006), striatal (Hill
et al., 2006) and dopaminergic neurons (Chung et al., 2011; Sun et al.,
2018), which are well known for their key role in determining learning,
memory and other cognitive functions. The TRPM2 channel is also
expressed in glial cells such as astrocytes (Lee et al., 2010; Wang et al.,
2016), particularly microglial cells that are known as the brain-resident
macrophage cells and thus are critical for immune responses (Jeong
et al., 2017; Kraft et al., 2004; Miyake et al., 2014; Miyanohara et al.,
2018; Syed Mortadza et al., 2017). Furthermore, TRPM2 channel ex-
pression has been documented in cerebrovascular endothelial cells
(Park et al., 2014) and pericytes (Jiang et al., 2017), which have vital
roles in neurovascular functions, such as regulation of cerebral blood
ﬂow (CBF) and formation of blood brain barrier (BBB). As discussed
next, recent studies have shown that the Aβ/ROS-induced TRPM2
channel activation leads to synaptic loss, neuronal death, microglial
activation and neuroinﬂammation, and neurovascular dysfunction,
providing strong evidence to imply an important role for the TRPM2
channel in multiple cellular and molecular mechanisms for AD patho-
genesis and progression.
3. Deletion of the TRPM2 expression halts Aβ-induced
neurodegeneration and cognitive impairment in an AD mouse
model
A large number of transgenic AD mice have bene generated and
these mouse models, despite bearing various caveats, have been highly
valuable for advancements in understanding AD pathogenesis and
preclinical testing of drugs (Jankowsky and Zheng, 2017). The APP/PS1
mice, which co-express a chimeric mouse/human APP with the Swedish
mutations (K670N and M671L) and human PS1 with the exon-9 dele-
tion (Jankowsky et al., 2003) and exhibit excessive generation of Aβ
and amyloid deposits in hippocampus and cortex in aged brains, are a
widely-used model for studying Aβ-induced pathogenesis. A recent
study has used this AD mouse strain to investigate the role of the
TRPM2 channel in mediating Aβ-induced neurodegeneration, micro-
glial activation and cognitive deﬁcit (Ostapchenko et al., 2015). As
previously documented, the APP/PS1 mice showed synaptic loss in the
hippocampus as evidenced by reduced expression of synapse-speciﬁc
protein synaptophysin, and microglial activation as indicated by upre-
gulated expression of the ionised calcium binding adapter molecule 1
protein, a microglial activation marker. Furthermore, the APP/PS1
mice exhibited severely impaired age-related spatial memory as ex-
amined using the Barnes test. Genetic deletion or knockout of the
TRPM2 expression (TRPM2-KO) in the wild-type (WT) C57BL/6 J mice
used to generate the APP/PS1 mice resulted in no signiﬁcant eﬀect.
However, TRPM2-KO in the APP/PS1 mice, while without discernible
change in amyloid deposition, completely reversed synaptic loss, mi-
croglial activation, and aging-related cognitive impairment. These re-
sults provide compelling evidence to support a critical role for the
TRPM2 channel in AD pathogenesis (Ostapchenko et al., 2015). How-
ever, this study has not addressed the molecular mechanisms by which
Aβ peptides induce the TRPM2 channel activation to signal neuro-
toxicity and adverse neurological outcomes.
4. TRPM2 channel as part of a positive feedback loop for Aβ42-
induced neuronal death
4.1. Role of the TRPM2 channel in ROS/Aβ42-induced neuronal death
An early electrophysiological study demonstrated expression of a
H2O2-sensitive Ca2+-permeable non-selective cation channel in cul-
tured rat striatal neurons with biophysical properties characteristic of
the recombinant TRPM2 channels and responsible for H2O2-induced
Ca2+ inﬂux to increase the intracellular Ca2+ concentrations ([Ca2+]i)
(Smith et al., 2003). A separate study showed that H2O2 induced Ca2+
responses and cell death in cultured rat striatal neurons and that such
H2O2-induced eﬀects were attenuated by overexpression of TRPM2-S
(Fonfria et al., 2005), a short alternative splicing variant that does not
form a functional channel on its own but, when co-expressed with
TRPM2-L, exerts a dominant negative inhibition of the TRPM2 channel
function (Zhang et al., 2003). These observations are in support of a
role for the TRPM2 channel in mediating H2O2-induced Ca2+ signalling
and neuronal death in striatal neurons. This study went on to enquire
the role of the TRPM2 channel in striatal neuronal death induced by
exposure to Aβ42 (Fonfria et al., 2005). Exposure of cultured striatal
neurons to 20 μM Aβ42 for 2 days led to signiﬁcant neuronal death,
which was also mitigated by overexpression of TRPM2-S. Thus, this
study, albeit using Aβ42 at a very high concentration, provided the ﬁrst
indication for a role of the TRPM2 channel in mediating Aβ42-induced
neuronal death. Our recent study has examined the role of the TRPM2
channel in cultured mouse hippocampal neurons in mediating neuronal
death induced by exposure to more pathologically relevant
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concentrations of H2O2 (30–300 μM) and Aβ42 (∼0.2-1 μM) (Li and
Jiang, 2018; Li et al., 2017b). Exposure to H2O2 or Aβ42 induced con-
centration-dependent neuronal death, which was suppressed by treat-
ment with 2-aminoethoxydiphenyl borate (2-APB) or N-(p-amylcinna-
moyl)anthranilic acid (ACA), which are known to inhibit the TRPM2
channel, prior to and during exposure to H2O2 or Aβ42. Moreover,
H2O2/Aβ42-induced hippocampal neuronal death was strongly atte-
nuated or completely prevented by TRPM2-KO. These results provide
pharmacological and genetic evidence that consistently supports a
crucial role for the TRPM2 channel in mediating ROS/Aβ42-induced
neuronal death of pathological relevance (Li and Jiang, 2018; Li et al.,
2017b).
4.2. Role of NOX-mediated ROS generation and PARP-1 activation in Aβ42-
induced TRPM2 channel activation and neuronal death
There is substantial evidence to indicate that ROS induces the
TRPM2 channel activation and causes cell death in neuronal (Fonfria
et al., 2005; Jia et al., 2011; Li et al., 2017b; Shimizu et al., 2013; Sun
et al., 2018) and non-neuronal cells via stimulating PARP-1 (Manna
et al., 2015; Mortadza et al., 2017; Zou et al., 2013). Our recent study
has therefore examined the role of ROS generation and PARP-1 acti-
vation in mediating Aβ42-induced TRPM2 channel activation and neu-
ronal death in cultured hippocampal neurons (Li and Jiang, 2018).
Exposure to Aβ42 markedly increased ROS generation, which was lar-
gely prevented by treatment, prior to and during exposure to Aβ42, with
apocynin or diphenyleneiodonium (DPI), two generic inhibitors of ni-
cotinamide adenine dinucleotide phosphate (NADPH)-dependent oxi-
dases (NOX), or GKT13831, a NOX1/4-selective inhibitor, and also by
treatment with Gö6967, a protein kinase C (PKC) inhibitor. Aβ42-in-
duced neuronal death was also strongly or completely inhibited by such
pharmacological interventions. These results are in good agreement
with the importance of NOX expression in oxidative stress-induced
neurodegeneration, particularly Aβ-induced AD pathogenesis
(Nayernia et al., 2014; Zekry et al., 2003). In addition, Aβ42-induced
neuronal death was strongly suppressed by treatment with PJ34 or
DPQ, two structurally diﬀerent PARP-1 inhibitors, prior to and during
exposure to Aβ42 (Li and Jiang, 2018). The above-mentioned study by
Fonfria et al reported a similar inhibition of Aβ42-induced striatal
neuronal death by treatment with SB-750139, another PARP-1 inhibitor
(Fonfria et al., 2005). Furthermore, there is evidence to suggest that
mitogen-activated protein kinase (MEK) and downstream extracellular
signal-regulated kinase (ERK) signalling pathway is important in reg-
ulating oxidative stress-induced PARP-1 activation in microglial cells,
oligodendrocytes and lymphocytes (Akhiani et al., 2014; Domercq
et al., 2013; Kauppinen et al., 2006). Consistently, Aβ42-induced hip-
pocampal neuronal death was completely prohibited by treatment with
U0126, a MEK/ERK inhibitor, prior to and during exposure to Aβ42 (Li
and Jiang, 2018). Taken together, these ﬁndings suggest that PKC/
NOX-mediated ROS generation and subsequent activation of MEK/ERK
and PARP-1 mediate Aβ42-induced TRPM2 channel activation and
neuronal death in hippocampal neurons (Fig. 2).
4.3. TRPM2-mediated alterations of intracellular Ca2+ and Zn2+
homeostasis in Aβ42-induced neuronal death
Intracellular Ca2+ and Zn2+ are important in numerous biochem-
ical and physiological processes but it is also well recognized that dis-
ruption in the intracellular Ca2+ and Zn2+ homeostasis is highly det-
rimental to cell survival, particularly for neurons (Alzheimer’s
Association Calcium Hypothesis, 2017; Berridge, 2010; Berridge et al.,
2003; Corona et al., 2011; Ji and Weiss, 2018; LaFerla, 2002; Li et al.,
2015; Overk and Masliah, 2017; Shuttleworth and Weiss, 2011;
Syntichaki and Tavernarakis, 2003; Thibault et al., 2007; Zundorf and
Reiser, 2011). Several recent studies have gathered evidence to suggest
that the TRPM2 channel functions as a Ca2+-permeable channel on the
cell surface and mediates ROS-induced extracellular Ca2+ inﬂux to
raise the [Ca2+]i in striatal, cortical, hippocampal and dopaminergic
neurons (Fonfria et al., 2005; Kaneko et al., 2006; Li et al., 2017b; Sun
et al., 2018). Such TRPM2-mediated Ca2+ signalling in cortical neurons
has been proposed to be important in mediating ROS-induced neuronal
death (Kaneko et al., 2006). In striatal neurons, exposure to 20 μM Aβ42
induced a detectable increase in the [Ca2+]i. Such Ca2+ response was
antagonized by treatment with SB-750139 or by overexpression of
TRPM2-S (Fonfria et al., 2005), supporting a role for the TRPM2
channel in Aβ42-induced Ca2+ signalling. However, it is yet unclear
how critical such TRPM2-mediated Ca2+ signalling is in Aβ42-induced
neuronal death. As shown in our previous study, TRPM2 channel acti-
vation is required for a salient rise in the intracellular Zn2+ con-
centration ([Zn2+]i) in hippocampal neurons during reperfusion fol-
lowing transient ischemia in vivo and in vitro and such alterations in the
intracellular Zn2+ homeostasis are strongly correlated with neuronal
death (Ye et al., 2014). In addition, direct exposure of cultured hip-
pocampal neurons to H2O2 can lead to an increase in the [Zn2+]i that is
strongly dependent of extracellular Ca2+ (Li et al., 2017b; Ye et al.,
2014), which is consistent with the importance of the Zn2+ and Ca2+
synergism in inducing neuronal death (Ji and Weiss, 2018). Our recent
study shows that exposure to Aβ42 up to 1 μM elevated the [Zn2+]i but
failed to evoke any measureable increase in the [Ca2+]i in hippocampal
neurons (Li and Jiang, 2018). Both H2O2/Aβ42-induced increase in the
[Zn2+]i and neuronal death were completely prevented by treatment
with PJ34 or 2-APB, and by TRPM2-KO as well as by treatment with
TPEN used as a Zn2+-speciﬁc chelator (Li and Jiang, 2018; Li et al.,
2017b; Ye et al., 2014). It is worth pointing out here that whether the
TRPM2 channel is permeable to Zn2+ still remains a matter of further
investigation (Li and Jiang, 2018; Li et al., 2017b). Regardless, all the
evidence from pharmacological and genetic interventions points to a
Fig. 2. The role of the TRPM2 channel in hippocampal neurons in a vi-
cious positive feedback loop mechanism driving Aβ42/ROS-induced neu-
ronal death.
Summary of the positive feedback loop mechanism proposed for Aβ42-induced
TRPM2 channel activation and neuronal death in hippocampal neurons.
Exposure to Aβ42 activates protein kinase C (PKC) and NADPH-dependent
oxidases (NOX), leading to ROS generation. ROS activates mitogen-activated
protein kinase (MEK) and downstream extracellular signal-regulated kinase
(ERK) to stimulate poly(ADPR) polymerase-1 (PARP-1) in the nucleus for ADPR
generation. ADPR opens the TRPM2 channel on the cell surface that mediates
extracellular Ca2+ inﬂux. ROS may also induce lysosomal membrane permea-
tion (LMP), resulting in lysosomal dysfunction and lysosomal Zn2+ release to
the cytosol. ADPR, in synergy with Ca2+, opens the TRPM2 channel located in
the mitochondria (presumably in the inner membrane), resulting in mi-
tochondrial Zn2+ accumulation. Mitochondrial Zn2+ accumulation triggers
mitochondrial dysfunction, cytochrome-c release and ROS generation.
Mitochondrial ROS generation further elevates the ROS levels and thereby
forms a vicious positive feedback to cause lysosomal and mitochondrial dys-
functions and ultimately drive neurons to die.
L.-H. Jiang et al. Ageing Research Reviews 47 (2018) 67–79
70
crucial role that the TRPM2 channel plays in mediating ROS/Aβ42-in-
duced alterations in the intracellular homeostasis of Ca2+ and parti-
cularly Zn2+, that lead to neuronal death.
Single cell imaging studies in conjunction with using intracellular
organelle speciﬁc markers have revealed a low level of intracellular
Zn2+ in untreated hippocampal neurons that exist in discrete puncta
being mainly located within the lysosomes but not mitochondria or
endoplasmic reticulum (Li and Jiang, 2018; Li et al., 2017b; Ye et al.,
2014). Exposure to H2O2 or Aβ42 induced an increase in the [Zn2+]i
that was accompanied by loss of lysosomal Zn2+ and, additionally, loss
of LysoTracker staining that indicates lysosomal dysfunction. Exposure
to Aβ42 also resulted in a signiﬁcant reduction in acridine orange
staining in hippocampal neurons, further supporting Aβ42-induced ly-
sosomal dysfunction. A previous study showed that H2O2 promoted
lysosomal membrane permeation (LMP) in hippocampal neurons
leading to neuronal death (Hwang et al., 2008). It is tempting to
speculate, although supporting evidence still awaits, that such a me-
chanism is responsible for Aβ42-induced lysosomal dysfunction and
contributes to Aβ42-induced hippocampal neuronal death (Fig. 2). Aβ42-
induced lysosomal dysfunction and increase in the [Zn2+]i were cur-
tailed by treatment with TPEN, PJ34 or 2-APB, and also by TRPM2-KO
(Li and Jiang, 2018). Interestingly, exposure to baﬁlomycin, which is
known to induce lysosomal dysfunction, increased the [Zn2+]i in hip-
pocampal neurons, like exposure to H2O2 or Aβ42. Collectively, these
observations are consistent with the idea that lysosomal dysfunction
acts as a mechanism for Aβ42-induced lysosomal Zn2+ release to in-
crease the [Zn2+]i. As introduced above, the TRPM2 channel has been
described to be located in the lysosomes, where it functions as a Ca2+
release channel in pancreatic β-cells, dendritic cells and endothelial
cells (Abuarab et al., 2017; Lange et al., 2009; Manna et al., 2015;
Sumoza-Toledo et al., 2011). Moreover, recent studies provide evidence
to suggest that the lysosome-residing TRPM2 channel is critical for
H2O2-induced lysosomal Zn2+ release and cell death in pancreatic β-
cells and endothelial cells (Abuarab et al., 2017; Manna et al., 2015).
Further eﬀorts are needed to clarify whether the TRPM2 channel is
present in the lysosomes in hippocampal neurons and, if it is true,
whether it has a role in mediating ROS/Aβ42-induced lysosomal Zn2+
release and neuronal death.
Single cell imaging studies have also shown that exposure to H2O2
or Aβ42 disrupted mitochondrial Zn2+ homeostasis and impaired mi-
tochondrial functions in cultured hippocampal neurons (Li and Jiang,
2018; Li et al., 2017b). Exposure to H2O2 or Aβ42 increased the Zn2+
level in the mitochondria, which was abolished by treatment with
TPEN, PJ34 or 2-APB, and by TRPM2-KO. Baﬁlomycin-induced lyso-
somal dysfunction also led to mitochondrial Zn2+ accumulation. These
results together support the notion that mitochondrial Zn2+ accumu-
lation occurs as a sequela of lysosomal dysfunction and lysosomal Zn2+
release (Li and Jiang, 2018; Li et al., 2017b). Surprisingly, baﬁlomycin-
induced mitochondrial Zn2+ accumulation was also prevented by
treatment with PJ34 or 2-APB, and by TRPM2-KO, indicating strong
dependence of the TRPM2 channel. Such observations raised an intri-
guing question with respect to the expression and function of the
TRPM2 channel in the mitochondria. Both confocal imaging of the
subcellular location of the TRPM2 immunoreactivity in cultured hip-
pocampal neurons and western blotting analysis of proteins in isolated
mitochondria consistently suggest mitochondrial location of the TRPM2
channel (Li and Jiang, 2018). In further support of this notion, treat-
ment with ADPR, the TRPM2 channel speciﬁc activator, induced sub-
stantial Zn2+ accumulation in individual mitochondria isolated from
WT but not TRPM2-KO hippocampal neurons. In addition, ADPR-in-
duced mitochondrial Zn2+ accumulation was only observed in the
presence but not in the absence of Ca2+, consistent with Ca2+ being
critical for ADPR-induced TRPM2 channel activation in hippocampal
neurons (Olah et al., 2009; Ostapchenko et al., 2015; Ye et al., 2014).
Mitochondrial location of the TRPM2 channel and requirement for
ADPR-induced mitochondrial Zn2+ accumulation were nicely
recapitulated in HEK293 cells by introducing heterologous expression
of the human TRPM2 channel (Li and Jiang, 2018). Taken together,
these results have led to the proposal that the TRPM2 channel is located
in the mitochondria and plays an important role in determining mi-
tochondrial Zn2+ accumulation. However, further eﬀorts are required
to elucidate whether the TRPM2 channel itself or distinct TRPM2-de-
pendent molecular mechanisms mediate mitochondrial Zn2+ accumu-
lation. The TRPC3 channel, a member of the TRPC subfamily, has been
reported to be located in the mitochondria and regulate mitochondrial
Ca2+ homeostasis (Feng et al., 2013). It is also interesting to investigate
whether the TRPM2 channel participates in mitochondrial Ca2+
homeostasis as well as mitochondrial Zn2+ homeostasis, as both are
known to be critical in determining the neuronal mitochondrial func-
tion (Ji and Weiss, 2018).
Studies examining the brains of AD patients and AD mouse models
have gathered a large body of evidence that supports a role for mi-
tochondrial dysfunction and associated oxidative stress in AD-related
pathologies (Fukui and Moraes, 2008; Kerr et al., 2017; Maruszak and
Zekanowski, 2011; Mattson et al., 2008; McManus et al., 2011;
Onyango, 2018; Swerdlow et al., 2014; Wang et al., 2014). Our recent
studies further considered the role of the TRPM2 channel, particularly
TRPM2-dependent mitochondrial Zn2+ accumulation, in H2O2/Aβ42-
induced mitochondrial dysfunction and mitochondrial ROS generation
in hippocampal neurons (Li and Jiang, 2018; Li et al., 2017b). A pre-
vious study reported mitochondrial fragmentation, mitochondrial im-
pairment and oxidative stress in neurons in the close vicinity of amyloid
plaques (Xie et al., 2013) in the APP/PS1 mice, which co-express the
chimeric mouse/human APP with the Swedish mutations and human
PS1 carrying the A246E mutation (Borchelt et al., 1997). In consistency
with such in vivo observations, our recent studies show that exposure to
H2O2 or Aβ42 induced tabular-to-fragmented change in the mitochon-
drial morphology, release of cytochrome-c, and mitochondrial ROS
generation (Li and Jiang, 2018; Li et al., 2017b). Interestingly, H2O2/
Aβ42-induced morphological change of the mitochondria and mi-
tochondrial ROS generation were abolished by treatment with TPEN,
PJ34 or 2-APB, and by TRPM2-KO (Li and Jiang, 2018; Li et al., 2017b).
In addition, baﬁlomycin-induced lysosomal dysfunction potently sti-
mulated mitochondrial ROS generation, which was also blocked by
treatment with PJ34 or 2-APB, and by TRPM2-KO (Li and Jiang, 2018).
These observations have led us to suggest that TRPM2-dependent mi-
tochondrial Zn2+ accumulation initiates ROS/Aβ42-induced mitochon-
drial dysfunction and neuronal death (Fig. 2).
PKC/NOX-mediated ROS generation, as discussed above, is crucial
in Aβ42-induced hippocampal neuronal death. Interestingly, inhibition
of PKC or NOX also strongly suppressed Aβ42-induced lysosomal dys-
function and lysosomal Zn2+ release and, furthermore, mitochondrial
Zn2+ accumulation and mitochondrial dysfunction (Li and Jiang,
2018). These results suggest that Aβ42-induced PKC/NOX-mediated
ROS generation acts as a mechanism that initiates lysosomal dysfunc-
tion and lysosomal Zn2+ release and subsequent TRPM2-dependent
mitochondrial Zn2+ accumulation and mitochondrial dysfunction. In
particular, these ﬁndings have led us to hypothesize, as summarized in
Fig. 2, that mitochondrial ROS generation closes in a vicious positive
feedback loop to sustain or build up oxidative stress and ultimately
drive neuronal death without the need of further or continuous ex-
posure to ROS or Aβ42 (Li and Jiang, 2018). Such a mechanism, while
still remaining hypothetic and needing further investigations, oﬀers
some explanation for the poor outcomes of anti-Aβ therapeutics alone
treating AD at the later stage.
5. TRPM2 channel in Aβ42-induced microglial cell activation and
neuroinﬂammation
5.1. Microglial cell activation in AD-related neuroinﬂammation
Microglial cells, the major cell population in the brain, are
L.-H. Jiang et al. Ageing Research Reviews 47 (2018) 67–79
71
functionally similar to macrophage cells in the systemic immune
system, and work together with other glial cells and the cerebrovascular
unit to uphold an optimal environment for neurons in the brain to
function. In the healthy brain, microglial cells assume a ramiﬁed
morphology deﬁned by small cell body with elongated and branched
processes. These cells unceasingly scrutinize the brain parenchyma and
eliminate cellular debris (Colonna and Butovsky, 2017; Hong and
Stevens, 2016; Wolf et al., 2017). Microglial cells are readily activated
by damage-associated molecular patterns (DAMP) molecules released
by host cells such as Aβ or pathogen-associated molecular patterns
(PAMP) molecules from infection with lipopolysaccharide (LPS) being
one such example. Upon activation, microglial cells adopt distinct
morphologies characterized by enlarged cell body and retracted pro-
cesses. Activated microglial cells can initiate potent inﬂammatory re-
sponses by generating a number of pro-inﬂammatory mediators, in-
cluding ROS and cytokines, to restore the brain homeostasis. It should
be pointed out, microglial cells have a protective role in AD by clearing
Aβ, but such a beneﬁcial capacity deteriorates and eventually becomes
ineﬃcient with aging or upon exposure to excessive Aβ. However, there
is a large volume of evidence from studies examining the brains of AD
patients and rodent AD models to support that chronic or dysregulated
activation of microglial cells and alterations in their activation states, in
concerted actions with DAMP molecules released by degenerating
neurons, can create a vicious positive feedback that results in genera-
tion of excessive proinﬂammatory mediators to damage synapses and
neurons, a process collectively termed neuroinﬂammation, and thus
restoration of the normal functional states of microglia has been pro-
posed as a therapeutic approach to AD (Block et al., 2007; Colonna and
Butovsky, 2017; Glass et al., 2010; Heneka et al., 2015, 2014; Heppner
et al., 2015; Minter et al., 2016; Mosher and Wyss-Coray, 2014; Perry
and Holmes, 2014; Prokop et al., 2013; Ransohoﬀ, 2016; Spangenberg
and Green, 2017; von Bernhardi et al., 2010; Wes et al., 2016; Wolf
et al., 2017). Aβ-induced neuroinﬂammation via generation by micro-
glial cells of excessive neurotoxic cytokines such as interleukin (IL)-1β,
tumour necrosis factor (TNF)-α and IL6 plays an important role in AD
pathogenesis and progression (Alam et al., 2016; Block et al., 2007;
Colonna and Butovsky, 2017; Heneka et al., 2015; Heppner et al., 2015;
Hong et al., 2016; Liu and Hong, 2003; Minter et al., 2016;
Spangenberg and Green, 2017; White et al., 2017; Wyss-Coray and
Rogers, 2012). As already discussed above, a recent study using the
APP/PS1 mice has shown that TRPM2-KO prevented Aβ-induced mi-
croglial cell activation in vivo (Ostapchenko et al., 2015). Consistently
with such an in vivo study, studies from us and other researchers using
cultured microglial cells provide evidence to support an important role
of the TRPM2 channel in Aβ42-induced microglial cell activation and,
additionally, generation of IL-1β and TNF-α (Syed Mortadza et al.,
2018; Aminzadeh et al., 2018). Moreover, these in vitro studies have
gained further insights into the molecular or signalling mechanisms
underlying Aβ42-induced TRPM2 channel activation.
5.2. Role of the TRPM2 channel in coupling Aβ42-induced ROS generation
to NLRP3 inﬂammasome activation and IL-1β generation
IL-1β is a master pro-inﬂammatory cytokine with a key role in in-
nate immunity (Heneka et al., 2014). IL-1β generation commonly re-
quires two signals named priming and activation signals (Fig. 3A). LPS,
derived from Gram-negative bacteria and often acting as a priming
signal, interacts with the Toll-like receptor 4 (TLR4) and thereby acti-
vates its downstream signalling pathway that leads to synthesis of pro-
IL-1β, the biologically inactive precursor protein. Aβ42 is a well-re-
cognized activation signal that promotes assembly and activation of the
multi-protein complex NLRP3 inﬂammasome in the cytosol, composed
of the nucleotide binding domain-containing leucine-rich repeat protein
3 (NLRP3), adapter protein apoptosis-associated speck-like protein, and
procaspase-1. The NLRP3 inﬂammasome serves a platform for recruit-
ment of pre-caspase-1 and activation of caspase-1 by cleavage and
subsequently caspase-1 converts pro-IL-1β into IL-1β. A recent study
has shown that genetic interruption of the NLRP3 inﬂammasome acti-
vation in the APP/PS1 mice, which co-express the chimeric mouse/
human APP with the Swedish mutations and human PS1 with exon-9
deletion (Jankowsky et al., 2003), reduced the ability of microglial cells
to generate IL-1β and enhanced Aβ clearance (Heneka et al., 2013).
These results support a role for Aβ-induced NLRP3 inﬂammasome ac-
tivation and IL-1β generation by activated microglial cells in AD pa-
thogenesis and progression (Heneka et al., 2013, 2014), leading to the
growing interest in the NLRP3 inﬂammasome as a therapeutic target for
treatment of AD (White et al., 2017). It is well-known that a great
number of DAMP/PAMP molecules, despite the striking diﬀerence in
their structures, can activate the NLRP3 inﬂammasome in immune cells
including microglial cells by stimulating ROS generation, particularly
mitochondrial ROS generation, and inducing extracellular Ca2+ inﬂux
(Gong et al., 2018; Hafner-Bratkovic and Pelegrin, 2018; Song et al.,
2017; Tschopp and Schroder, 2010). A recent study has examined the
role of the TRPM2 channel in IL-1β generation by LPS-primed macro-
phage cells after exposure to silica, alum or charged lipids. IL-1β gen-
eration induced by these particulate crystals was impaired by TRPM2-
KO or upon removal of extracellular Ca2+ inﬂux, demonstrating a cri-
tical role for the TRPM2 channel or more speciﬁcally TRPM2-mediated
Ca2+ inﬂux in coupling mitochondrial ROS generation to NLRP3 in-
ﬂammasome activation and IL-1β generation (Zhong et al., 2013). A
more recent study has revealed a similar role for the TRPM2 channel in
mediating Aβ42-induced NLRP3 inﬂammasome activation and IL-1β
maturation in LPS-primed microglial cells (Aminzadeh et al., 2018).
This study shows that exposure to 10 μM Aβ42 induced mitochondrial
ROS generation and IL-1β generation, both of which were strongly in-
hibited or completely abolished by pre-treatment with a high con-
centration of DPI (20 μM) as a mitochondrial ROS inhibitor. Aβ42-in-
duced IL-1β generation was also reduced by pre-treatment with
VAS2870 or (2R, 4R)-4-aminopyrrolidine-2,4-dicarboxylate (APDC),
NOX inhibitors, N-acetylcysteine (NAC), a ROS scavenger, or DPQ. Aβ42
induced a signiﬁcant increase in the [Ca2+]i, which was markedly
suppressed by treatment with DPI, VAS2870, or DPQ. Furthermore,
Aβ42-induced increase in the [Ca2+]i was observed only in the Ca2+-
containing but not Ca2+-free solutions and was also reduced by treat-
ment with BAPTA-AM, a membrane-permeable Ca2+ chelator, to buﬀer
the increase in the [Ca2+]i. Finally, Aβ42-induced caspase-1 activation,
examined by western blotting, was inhibited by treatment with DPQ or
BAPTA-AM. Overall, the study provides pharmacological evidence to
suggest, as summarized in Fig. 3A, that the TRPM2 channel, particu-
larly TRPM2-mediated Ca2+ inﬂux, is critical in Aβ42-induced IL-1β
generation by coupling mitochondrial and NOX-mediated ROS gen-
eration to activation of the NLRP3 inﬂammasome and caspase-1.
5.3. TRPM2 channel is essential for Aβ42-induced microglial cell activation
and TNF-α generation
TNF-α represents another proinﬂammatory cytokines that plays an
important role in Aβ-induced AD-related pathologies via multiple and
distinctive cellular and molecular mechanisms. It can induce neuronal
death directly via activation of the TNF death receptor and also in-
directly through microglial cell activation and generation of neurotoxic
proinﬂammatory mediators (Alam et al., 2016; Block et al., 2007; Doll
et al., 2015; Kalliolias and Ivashkiv, 2016). Thus, chronic neuron-spe-
ciﬁc expression of TNF-α enhanced local inﬂammation and neuronal
death in the triple-transgenic AD (3xTg-AD) mice (Janelsins et al.,
2008), which co-express human APP with the Swedish mutations and
human tau with P30IL mutation together with PS1 with M146 V mu-
tation (Oddo et al., 2003), whereas deletion of the TNF-α expression
attenuated Aβ generation, amyloid deposition and microglial activation
in 5XFAD AD mice (Paouri et al., 2017), in which co-expression of
human APP with the Swedish (K670 N/M671 L), Florida (I716 V) and
London (V717I) mutations and human PS1 with M146 L and L286 V
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mutations results in almost exclusive generation of Aβ42, amyloid de-
position and memory impairment (Oakley et al., 2006). Consistently,
genetic ablation of the TNF type 1 death receptor (TNFR1) expression
suppressed Aβ generation and cognitive dysfunction in the APP23 AD
mice (He et al., 2007), in which expression of human APP with the
Swedish mutations results in senile plaque formation in the cerebral
cortex and hippocampus and neuronal loss in CA1 of the hippocampus
(Sturchler-Pierrat et al., 1997). These ﬁndings support a signiﬁcant role
for TNF-α and its receptor TNFR1 in Aβ-related pathogenesis, leading to
the proposal of inhibiting TNF-α generation as a therapeutic strategy
treating AD. Our recent study has examined the role of the TRPM2
channel in mediating Aβ42-induced microglial cell activation and TNF-
α generation in cultured microglial cells (Syed Mortadza et al., 2018).
Exposure to Aβ42 at 30–300 nM induced concentration-dependent
change in the microglial cell morphology, and an increase in the ex-
pression and secretion of TNF-α, as shown by immunocytochemistry
and enzyme-linked immunosorbent assay, respectively. Aβ42-induced
changes in the cell morphology and TNF-α generation were prevented
by pre-treatment with 2-APB and also by TRPM2-KO, highlighting a key
role of the TRPM2 channel in mediating Aβ42-induced microglial cell
activation and TNF-α generation. Aβ42-induced increase in the [Ca2+]i
was prevented by pre-treatment with 2-APB or by TRPM2-KO, and only
observed in the extracellular Ca2+-containing but not Ca2+-free solu-
tions (Syed Mortadza et al., 2018), demonstrating a major role for the
TRPM2 channel in Aβ42-induced Ca2+ signalling (Fig. 3B). This is
consistent with a previous study showing cell surface expression of the
TRPM2 channel in microglial cells and its critical role in mediating
Ca2+ inﬂux (Kraft et al., 2004). We have further demonstrated that
exposure to Aβ42 induced massive ROS generation and nuclear PARP-1
activation. Aβ42-induced ROS generation and PARP-1 activation were
strongly suppressed by pre-treatment with DPI, GKT137831 or Phox-I2,
a NOX2-speciﬁc inhibitor, and also by pre-treatment with chelerythrine
chloride (CTC), a PKC inhibitor. Aβ42-induced increase in the [Ca2+]i
was also strongly inhibited by such pharmacological treatments as well
as treatment with PJ34 or DPQ. Taken together, these results indicate
that PKC/NOX-mediated ROS generation and subsequent PARP-1 acti-
vation are critical for Aβ42-induced TRPM2 channel activation in
microglial cells that leads to extracellular Ca2+ inﬂux and an increase
in the [Ca2+]i (Fig. 3B). A previous study showed that TRPM2-medi-
ated Ca2+ inﬂux in monocytes activated PYK2, a Ca2+-sensitive tyr-
osine kinase, and its downstream mitogen-activated kinases MEK/ERK
in response to H2O2 (Yamamoto et al., 2008). Similarly, Aβ42-induced
increase in the [Ca2+]i and PARP-1 activation in microglial cells were
prevented by pre-treatment with PF431396, a PYK2 inhibitor, or
U0126, a MEK/ERK inhibitor (Syed Mortadza et al., 2018). Of notice,
Aβ42-induced PARP-1 activation was signiﬁcantly reduced but not
completely abolished by TRPM2-KO. The Aβ42-induced PARP-1 activity
in TRPM2-KO microglial cells was eliminated by pre-treatment with
DPI, GKT137831, Phox-I2 or CTC, but was not altered by pre-treatment
with PF431396 or U0126 (Syed Mortadza et al., 2018). These dis-
criminating results suggest that Aβ42-induced PKC/NOX-mediated ROS
generation and PARP-1 activation act as the mechanism initiating
TRPM2 channel activation, and subsequent TRPM2 channel-mediated
Ca2+ inﬂux and activation of the PYK2/MEK/ERK signalling pathway
provide a positive feedback mechanism to maintain the TRPM2 channel
activation (Fig. 3A). Aβ42-induced microglial cell activation and TNF-α
generation were eﬀectively prevented by treatment with PF431396 or
U0126, supporting the importance of such PYK2/MEK/ERK signalling
pathway-mediated positive feedback mechanism in mediating Aβ42-
induced microglial cell activation and TNF-α generation.
Collectively, these recent in vitro and in vivo studies, as illustrated in
Fig. 3, provide compelling evidence that consistently supports the
TRPM2 channel as a previously unrecognized mechanism mediating
Aβ42-induced generation of proinﬂammatory cytokines and AD-related
neuroinﬂammation (Wei et al., 2018).
6. TRPM2 channel in cerebral endothelial cells for Aβ-induced
neurovascular dysfunction
Cerebral endothelial cells form part of the neurovascular unit by
lining the inner blood vessel wall and thus play a vital role in regulating
CBF and maintaining BBB function (Iadecola, 2017). While ROS-in-
duced cerebrovascular endothelial dysfunction is a well-known risk
factor that enhances the susceptibility to brain pathologies such as
Fig. 3. The role of the TRPM2 channel in microglial cells
in Aβ42-induced mechanisms for microglial cell activation
and generation of proinﬂammatory IL-1β and TNF-α.
A, summary of the molecular/signalling mechanisms proposed
for Aβ42-induced TRPM2 channel activation and generation of
interleukin (IL)-1β by microglial cells primed with lipopoly-
saccharide (LPS). LPS promotes synthesis of pro-IL-1β via ac-
tivation of the Toll-like receptor 4 (TLR4). Aβ42 stimulates
mitochondrial and NADPH-dependent (NOX)-mediated ROS
generation, which in turn activates poly(ADPR) polymerase
(PARP) and poly(ADPR) glycohydrolase (PARG) for ADPR
generation. Activation by ADPR of the TRPM2 channel on the
cell surface results in extracellular Ca2+ inﬂux and an increase
in the intracellular Ca2+ concentration that triggers activation
of the NLRP3 inﬂammasome and caspase-1. Caspase-1 con-
verts pro-IL-1β to IL-1β. B, summary of the molecular/sig-
nalling mechanisms for Aβ42-induced TRPM2 channel activa-
tion and generation of tumour necrosis factor (TNF)-α by
microglial cells. Aβ42 induces NOX-mediated ROS generation.
ROS in turn activate the TRPM2 channel on the cell surface via
stimulating PARP-1 mediated ADPR generation in the nucleus.
TRPM2 channel activation results in extracellular Ca2+ inﬂux
and an increase in the intracellular Ca2+ concentration, which
triggers the expression and secretion of TNF-α. TRPM2-de-
pendent Ca2+ inﬂux activates the Ca2+-sensitive tyrosine ki-
nase PYK2 and downstream mitogen-activated kinase (MEK)
and extracellular signal-regulated kinase (ERK) to further sti-
mulate PARP-1. Such signalling pathway acts as a positive
feedback mechanism for TRPM2 channel activation and TNF-α generation. Microglial generation of IL-1β and TNF-α is critical in contributing to Aβ-induced
neuroinﬂammation.
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atherosclerosis and stroke, there is growing evidence to support a role
of Aβ-induced ROS generation and subsequent impairment in cere-
brovascular endothelial function in predisposing to AD (Iadecola, 2013,
2017; Koizumi et al., 2016; McDade et al., 2014; Purnell et al., 2009;
Sweeney et al., 2018; Toledo et al., 2013; Zlokovic, 2011). It has been
well established that the TRPM2 channel function as a cell surface
Ca2+-permeable channel in pulmonary artery and microvascular en-
dothelial cells that mediates ROS-induced Ca2+ inﬂux to increase in the
[Ca2+]i and endothelial cell death and barrier dysfunction (Hecquet
et al., 2008, 2014; Mittal et al., 2018). A recent study has examined the
TRPM2 channel expression in cerebrovascular endothelial cells and its
role in Aβ-induced neurovascular dysfunction (Park et al., 2014). In the
CD31-positive immortalized mouse brain endothelial bEEND.3 cells,
intracellular application of Aβ40 as well as ADPR elicited sizable ionic
currents with a linear current-voltage relationship curve, and such
currents were sensitive to blockage by 2-APB or ACA, and prevented by
siRNA-mediated knockdown of the TRPM2 expression, indicating
functional expression of the TRPM2 channel and its activation by Aβ40.
Aβ40/ADPR-induced currents were also inhibited by pre-treatment with
PJ34, ADP-HPD, a PARG inhibitor, tetrakis(4-benzoic acid)porphyrin
chloride Mn(III) (MnTBAP), a ROS scavenger, gp91ds-tat, a NOX pep-
tide inhibitor, or L-NG-nitroarginine (L-NNA), a nitric oxide (NO) syn-
thase (NOS) inhibitor. Exposure to Aβ40 induced PARP-1 activation,
which was prevented by pre-treatment with MnTBAP, tempol, another
ROS scavenger, gp91ds-tat, L-NNA, or 5,10,15,20-tetrakis(4-sulfonato-
phenyl)porphyrinato iron(III) chloride (FeTPPS), a peroxynitrite de-
composition catalyst. Overall, these results support that Aβ40-induced
NOX-mediated ROS generation and constitutive NOS-mediated NO
generation, leading to peroxynitrite formation and subsequent activa-
tion of the PARP-1/PARG and TRPM2 channel in brain endothelial cells
(Fig. 4). In addition, exposure to Aβ40 induced an increase in the
[Ca2+]i and such Ca2+ responses were essentially inhibited by treat-
ment with 2-APB, ACA or TRPM2-speciﬁc siRNA, indicating a critical
role for the TRPM2 channel in Aβ40-induced Ca2+ signalling via med-
iating Ca2+ inﬂux, as described above in microglial cells (Fig. 3). This
study performed further experiments to examine the role of the TRPM2
channel in Aβ-induced neurovascular dysfunction in vivo (Park et al.,
2014) using the Tg2576 AD mice expressing human APP carrying with
the Swedish mutations (Hsiao et al., 1996). In the WT mice, neocortical
superfusion of 5 μM Aβ40 signiﬁcantly reduced the resting CBF and also
attenuated the increase in CBF induced by neural activity via whisker
stimulation or vasodilation via application of acetylcholine, an en-
dothelial-dependent vasodilator. Aβ40-induced reduction in the resting
CBF and the evoked increases in CBF were prevented by neocortical
application of FeTPPS, uric acid, another peroxynitrite scavenger, PJ34,
or ADP-HPD, and by genetic deletion of the PARP-1 expression. Fur-
thermore, such Aβ40-induced changes in CBF under the resting and
stimulated conditions were also eﬀectively prevented by neocortical
application of 2-APB or ACA, and by TRPM2-KO. In the Tg2576 AD
mice, the evoked increases in CBF were signiﬁcantly smaller compared
those observed in the WT mice. Such neurovascular dysfunction in the
Tg2576AD mice was fully restored by treatment with PJ34, ADP-HPD,
2-APB or ACA. Taken together, these results consistently support that
the TRPM2 channel is important in linking Aβ-induced ROS generation
to cerebrovascular dysfunction (Fig. 4), therefore revealing a distinct
cellular mechanism by which the TRPM2 channel is engaged in Aβ-
induced pathogenesis and progression (Koizumi et al., 2016; Park et al.,
2014).
7. Closing remarks and perspective
As the world population is continually aging, the number of the
elder people suﬀering from dementia will rise at an accelerated pace,
imposing immense social and ﬁnancial burdens on individuals and re-
lated families as well as severe pressure on the national healthcare
service. Development of eﬀective therapeutics to prevent or slow down
AD, the most common cause of age-related dementia, will bear para-
mount signiﬁcance in our endeavour to ﬁght dementia. The hope is still
living on that one day the anti-Aβ drugs currently under development
will turn to eﬀective AD-modifying therapeutics (Bachurin et al., 2017;
Mullard, 2016, 2017; van Dyck, 2018). Nonetheless, the vast dis-
appointments as a result of numerous ﬂopped clinical trials of anti-Aβ
drugs that have been witnessed over the recent few years call for urgent
needs to gain a more comprehensive insight into the complicated ae-
tiology of AD, identify new intervention targets and/or change the
approaches to research and development of therapeutics (Goldman
et al., 2018; Onyango, 2018; Rajendran and Paolicelli, 2018; Weinstein,
2018; Wes et al., 2016; White et al., 2017). As discussed in this review
and highlighted in Fig. 5, the emerging evidence from recent studies
leads to a novel ‘hypothesis’ that multiple TRPM2-mediated cellular
and molecular mechanisms cascade Aβ and oxidative damage to AD
pathologies. These new ﬁndings clearly support the multi-cellular hy-
pothesis for AD pathogenesis and progression (Goetzl and Miller, 2017).
In particular, the emerging role of the TRPM2 channel in sustaining a
vicious positive feedback loop driving neuronal death and neuroin-
ﬂammation may represent a potential pitfall that contributes to the
poor therapeutic outcomes of anti-Aβ interventions alone in AD pa-
tients. The new ﬁndings or the ‘hypothesis’ based on such ﬁndings leads
to the prospect of considering the TRPM2 channel as a novel drug target
for intervening AD and age-related dementia.
The recent studies have no doubt made considerable progress in
exposing the TRPM2 channel as a previously unrecognized mechanism
for oxidative damage implicated in neurodegenerative diseases such as
AD. Nevertheless, it is evident from the discussion presented above that
more investigations are essential to evolve a better understanding of the
TRPM2 channel nexus from Aβ and oxidative damage to AD patho-
genesis and progression. It is well-known that Zn2+ is abundant in
hippocampal neurons and can potently induce neuronal degeneration.
TRPM2 channel activation is critical in ROS/Aβ-induced alterations in
intracellular Zn2+ homeostasis, more speciﬁcally, lysosomal Zn2+ re-
lease and mitochondrial Zn2+ accumulation. However, direct evidence
is still short to show how the TRPM2 channel is involved in such dy-
namic intracellular Zn2+ homeostasis in hippocampal neurons, whether
the TRPM2 channel itself or TRPM2-dependent distinctive molecular
mechanisms mediate Zn2+ ﬂux from lysosomes or into mitochondria
and, importantly, how such alterations in the Zn2+ homeostasis in these
Fig. 4. The role of the TRPM2 channel in cerebral endothelial cells in Aβ-
induced endothelial dysfunction.
Summary of the molecular/signalling mechanism responsible for Aβ40-induced
TRPM2 channel activation in cerebral endothelial cells and endothelial dys-
function. Aβ40 via CD36 induces NADPH-dependent oxidase (NOX) activation
and ROS generation. Reaction of ROS with nitric oxide (NO) constitutively
generated by endothelial NO synthase (eNOS), leads to peroxynitrite formation
that stimulates poly(ADPR) polymerase-1 (PARP-1) and poly(ADPR) glycohy-
drolase (PARG) in the nucleus to generate ADPR. ADPR opens the TRPM2
channel, resulting in extracellular Ca2+ inﬂux and an increase in the in-
tracellular Ca2+ concentrations that triggers endothelial and neurovascular
dysfunction.
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intracellular organelles disrupt their functions and lead to neuronal
demise. Similarly, there is strong evidence from both in vivo and in vitro
studies for the importance of the TRPM2 channel in Aβ-induced mi-
croglial cell activation. Moreover, in vitro studies show critical re-
quirement of the TRPM2 channel for Aβ-induced generation of IL-1β
and TNF-α. As pointed out above, IL-6 is another proinﬂammatory
cytokine strongly implicated in Aβ-induced neuroinﬂammation for AD.
The TRPM2 channel has been shown to be required for LPS-induced IL-
6 generation from monocytes (Wehrhahn et al., 2010), but the role of
the TRPM2 channel in IL-6 generation by microglial cells remains un-
known. Further in vivo studies are needed to demonstrate that TRPM2-
dependent generation of IL-1β and TNF-α are critically responsible for
Aβ-induced neurotoxicity. The TRPM2 channel is also expressed in
astrocyte, another type of glial cells in the brain that is also actively
engaged in neuroinﬂammation (Leyns and Holtzman, 2017), but it re-
mains poorly understood whether the TRPM2 channel in astrocytes
contributes to Aβ-induced neuroinﬂammation. Our recent study shows
that exposure to nanoparticles induced TRPM2-mediated cell death in
pericytes via autophagy, leading to impairment in the BBB function
(Jiang et al., 2017). It will be attractive to investigate whether Aβ, like
nanoparticles, can also cause pericyte cell death and BBB disruption by
inducing the TRPM2 channel activation, contributing to neurovascular
function.
As introduced above, studies over the past few years have accu-
mulated strong evidence to demonstrate or implicate a critical role for
the TRPM2 channel in mediating a diversity of other oxidative stress-
related conditions as well as AD, leading to growing interest in TRPM2
channel inhibitors. An increasing number of chemicals have been
identiﬁed to inhibit the TRPM2 channel (Jiang et al., 2010). Recent
examples include ADPR analogues (Luo et al., 2018; Moreau et al.,
2013), curcumin (Kheradpezhouh et al., 2016), scalaradial (Starkus
et al., 2017), tyrphostin AG and related compounds (Shimizu et al.,
2014; Yamamoto et al., 2017) and tat-tagged M2NX peptide inhibitor
(Shimizu et al., 2016), with some of them having been reported to
exhibit selective inhibition towards the TRPM2 channel. Nevertheless,
the pharmacology of the TRPM2 channel currently remains still limited.
A majority of the recent studies have used genetic interventions in
combination with rodent disease models, but it is therapeutically im-
portant to explore whether the human TRPM2 channel plays similar
roles as have been revealed for the rodent TRPM2 channels. To this end,
selective and potent TRPM2 channel inhibitors, particularly BBB-pe-
netrable inhibitors, are highly desirable and prerequisite for providing
the proof of concept that the human TRPM2 channel is a plausible
target for AD therapeutics. With unceasing eﬀorts in advancing our
understanding of AD mechanisms, identifying new therapeutic targets
and formulating drug development strategies, eﬀective AD-modifying
treatments are hoped to be within the reach of patients aﬄicted with
debilitating conditions such as AD and dementia in the foreseeable
future.
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